DR . HEMMEL AMRANIA TITLE : FOUNDER & CEO COMPANY : DIGISTAIN LOCATION : LONDON
Clinical Scientist Dr . Hemmel
Amrania works in an oncology unit at Imperial College London and is the CEO of Digistain . He was awarded the Outstanding Research Prize at Imperial College & the Royal Innovation Award .
Distributing life-saving technology to women with breast cancer Breast cancer is the most common cancer for women worldwide . In 2020 , breast cancer caused approximately 685,000 deaths globally , but incidence rates vary geographically . The highest incidence rates are observed in developed countries , while breast cancer mortality rates are higher in less-developed regions . This discrepancy is due to differences in access to early detection , diagnosis and treatment .
Dr . Hemmel Amrania has a PhD in Physics from Imperial College London , focused on infrared optics and lasers and biomedical imaging . He ’ s now a Physicist in Cancer Diagnostics Development at Imperial College London , as well as the CEO of Digistain , a biotechnology research company which uses AI risk profiling technology which can be used in the treatment of breast cancer .
healthcare-digital
. com 125